Tofacitinib

Red

Brand Name(s):Xeljanz

Indication:Rheumatoid arthritis -moderate to severe
Psoriatic arthritis
Ulcerative Colitis – moderate to severely active in adults

Rationale:1,2,3

Considered:Apr-17

Review Date:Feb-25

Comments:
Tofacitinib for moderately to severely active ulcerative colitis
https://www.nice.org.uk/guidance/TA547

NICE Nov 19 -PRAC recommendations for caution with tofacitinib endorsed by CHMP
The recommendations that tofacitinib should be used with caution in patients with known risk factors for VTE, regardless of indication and dosage, have now been endorsed by Committee for Medicinal Products for Human Use (CHMP).

Drug Safety Update
Tofacitinib (Xeljanz): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
May 2019